BIO-TECHNE Corp
For the period ended Jun 30, 2026. Filed Aug 24, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2026 · Filed Aug 24, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 2. Properties
The Company owns the facilities that its headquarters and R&D Systems subsidiary occupy in Minneapolis, Minnesota. The Minneapolis facilities are utilized by both the Company’s Protein Sciences and Diagnostics and Spatial Biology segments.
The Minneapolis complex includes approximately 800,000 square feet of space in several adjoining buildings. Bio-Techne uses approximately 710,000 square feet of the complex for administrative, research, manufacturing, shipping and warehousing activities. The Company is currently leasing the remaining space in the complex as retail and office space. The Company also owns a 61,000 square foot facility in Saint Paul, Minnesota that is utilized for additional manufacturing capabilities and activities.
The Company owns a 16,000 square foot facility that its Bio-Techne Europe subsidiary occupies in Abingdon, England. This facility is utilized by the Company’s Protein Sciences and Diagnostics and Spatial Biology segments.
The Company owns a 9,000 square foot facility that its Canada subsidiaries occupy in Toronto, Canada. This facility is utilized by the Company’s Protein Sciences segment.
The Company owns a 53,000 square foot manufacturing facility in Wallingford, Connecticut. This facility is utilized by the Company’s Protein Sciences segment.
The Company leases the following material facilities, which are utilized by both the Company’s Protein Sciences segment and the Diagnostics and Spatial Biology segment. Certain locations are not named because they were not significant individually or in the aggregate as of the date of this report.
| | | | | | | |
|---|---|---|---|---|---|---|
| Subsidiary | | Location | | Type | | Square Feet |
| ProteinSimple | San Jose, California | Office/manufacturing/warehouse | 98,000 | |||
| Novus Biologicals | Centennial, Colorado | Office/warehouse | 74,000 | |||
| Bionostics | Devens, Massachusetts | Office/manufacturing | 70,000 | |||
| Cliniqa | San Marcos, California | Office/manufacturing/warehouse | 63,000 | |||
| PrimeGene | Shanghai, China | Office/manufacturing/lab | 59,000 | |||
| Advanced Cell Diagnostics | Newark, California | Office/manufacturing/warehouse | 56,000 | |||
| Asuragen | Austin, Texas | Office/manufacturing/warehouse | 47,000 | |||
| Tocris | Bristol, United Kingdom | Office/manufacturing/lab/warehouse | 41,000 | |||
| Bio-Techne China | Shanghai and Beijing, China | Office/warehouse | 34,000 | |||
| Lunaphore | | Tolochenaz, Switzerland | | Office/manufacturing/warehouse | | 26,000 |
| Bio-Techne Ireland | Dublin, Ireland | Warehouse | 25,000 | |||
| ProteinSimple Ltd. | Ottawa, Canada | Office/manufacturing/warehouse | 11,000 | |||
| Bio-Techne France | Rennes, France | Office/warehouse | 11,000 | |||
| Bio-Techne Germany | | Dusseldorf, Germany | | Office | | 11,000 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.